(Alliance News) - AstraZeneca PLC on Wednesday said its phase 3 Neptune trial of Imfinzi in combination with tremelimumab did not meet its primary endpoint of improving overall survival.
Neptune was a randomised, open-label trial of previously untreated patients with stage four non-small cell lung cancer. The primary analysis population was patients with a high number of mutations in their tumour DNA.
Within the primary analysis group, where patients had at least 20 mutations per megabase, the Imfinzi and tremelimumab combination failed to improve survival compared to standard-of-care chemotherapy.
Jose Baselga, executive vice president of Oncology R&D at Astra said: "We are fully committed to a deep analysis of the vast clinical and biomarker data from this trial to gain further insights to improve immuno-oncology approaches for patients with metastatic non-small cell lung cancer."
Imfinzi is currently being tested as a single therapy in the phase 3 Pearl trial and in combination with chemotherapy in the phase 2 Poseidon trial - with tremelimumab and without. Both trials will assess the drug as a treatment for stage 4 non-small cell lung cancer.
Astrazeneca (AZN)